Real-World Data on Subsequent Therapy for First-Line Osimertinib-Induced Pneumonitis: Safety of EGFR-TKI Rechallenge (Osi-risk Study TORG-TG2101).
Naoya NishiokaHisao ImaiMasahiro EndoAkifumi NotsuKosei DoshitaSatoshi IgawaHiroshi YokouchiTakashi NinomiyaTakaaki TokitoSayo SodaTakasato FujiwaraTetsuhiko AsaoShinji NakamichiTakahisa KawamuraMinehiko InomataKazuhisa NakashimaKentaro ItoYasuhiro GotoYukihiro UmedaSoichi HiraiRyota UshioKeiki YokooTakayuki TakedaTomoya FukuiMasashi IshiharaTakashi OsakiSousuke KuboTakumi FujiwaraChie YamamotoTakeshi TsudaNobumasa TamuraShinobu HosokawaYusuke ChiharaSatoshi IkedaNaoki FuruyaYoshiro NakaharaSatoru MiuraHiroaki OkamotoPublished in: Targeted oncology (2024)
Osimertinib rechallenge after initial pneumonitis was associated with significantly higher recurrence rates than conventional EGFR-TKI rechallenge.
Keyphrases
- epidermal growth factor receptor
- tyrosine kinase
- small cell lung cancer
- advanced non small cell lung cancer
- interstitial lung disease
- electronic health record
- diabetic rats
- big data
- high glucose
- free survival
- chronic myeloid leukemia
- systemic sclerosis
- machine learning
- idiopathic pulmonary fibrosis
- endothelial cells